Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The succinct history of this company:
Jam tomorrow never today
Another one which Catha Friel is heavy involved in, Amryt, an orphan-drugs company, which seeks a NASDAQ listing in the near -future.
Keep holding, this is one for the long-term. I predict significant upside here over the next 3 years.
For those interested in alternative Pharma stocks (if you're not, no problem - this is a shameless plug) Open Orphan AIM:ORPH is one I’d recommend keeping an eye on - Share price has performed well over the last 6 months and it's no surprise - CEO Cathal Friel predicts 40% growth a year on podcast below with 2 million of his own money invested. hxxps://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year
Their health databank a standout for me and is progressing well. ORPH recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of Open Orphan’s Genomic Health Data platform and will speed up its launch. The companies CCO Maurice Treacy is holding a live webinar on Wednesday 30th October 2019 at 19:00 (UK time) for those interested: https://vtm.clickmeeting.com/orph
Significant piece from the interims:
'I am also delighted to report that the collaboration and license deal established with Professor Bill Bachovchin of Tufts University Medical School is progressing very well. The opportunity to test the tumour targeting chemistry in the clinic as early as next year is well ahead of schedule and could be game-changing for Avacta. Doxorubicin is a $1bn drug despite severe cardiotoxicity issues that limits its effectiveness. In the case of Avacta's improved version of this drug, AVA6000 pro-Doxorubicin that is based on the Tufts technology, we have seen a dramatic improvement in safety in pre-clinical animal models. If we see a similar reduction in cardiotoxicity in humans in the planned phase I clinical trial of AVA6000 in 2020, then there is the potential for a major license deal that could generate a transformational, non-dilutive, upfront payment of tens of millions of dollars. This funding would support all our other programmes in future. We should also be able to apply the Tufts technology to improve the safety of a large number of other established chemotherapies and generate similar licensing opportunities. For this reason, we are prioritising this programme with respect to use of the proceeds of today's successful placing.'
Why on earth does this one keep falling? I have been invested in this one for many years - it's the cliched bottom-drawer for me.
From my point of view, I see Avacta as an ideal company to trade. The recent agreement with ADC Therapeutics is valued at around say, £300mil, that's a potential total of £680 mil of future earnings, but there is no timeline for these payments so receipts will be sporadic. Next year is said to be "exciting" as far as new contracts for Diagnostics goes, so we will expect a number of announcements which hopefully will create spikes, and then on to phase 1 clinical trials which should also create interest over a few years. I would consider buying in with a reasonable holding in the new year with the hope of building a good amount of cash over the next 4-5 years.
Very disappointing RNS in my view. I just don’t see light at the end of the tunnel. I know you have to be patient with Pharmas but this has gone from over £1 share to nearly 10p and losses are increasing
...and then avoid buying!
RNS
Placing done
Further deals happening as mentioned by the company !’
wait until it drops under 10p
but a pity the SP continues to fall as IIs have no solid grounds to stay invested. With the number of agreements in place increasing and with increasing income it ought to be possible to have some indication of the expected total without breaching the terms of individual commercial agreements. Without more clarity the SP decline may continue. The moment income covers costs and the possibility of more funding / dilution is removed, the business case is not made.
DYOR